StockNews.AI
APVO
StockNews.AI
186 days

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

1. 100% of patients in Cohort 1 achieved remission in AML trial. 2. Promising 59% stable disease rate in ALG.APV-527 Phase 1 trial.

Earnings
-8.24%Current Return
VS
0%S&P 500
$3.6402/14 08:09 AM EDTEvent Start
$3.3402/17 08:15 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

The 100% remission rate indicates strong efficacy, potentially driving APVO shares upward, similar to past successes in oncology trials that saw drastic stock increases.

How important is it?

The trial results directly reflect APVO’s core business focus, showcasing its potential market impact and attractiveness to investors.

Why Long Term?

Positive trial results suggest future revenue potential, trailing lengthy approval processes, likely influencing APVO over time.

Related Companies

APVO
100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Case for Continued Development of First-in-Class Anti-Cancer Agent SEATTLE, WA / ACCESS Newswire / February 14, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the year ended December 31, 2024 and provided a business update. Business Update "2024 was a successful year for Aptevo, as we've demonstrated the power of our science and our commitment to advancing oncology care.

Related News